Peptide half-life determines how long a compound remains active in the body and directly informs optimal injection timing and frequency. A peptide with a 10-minute half-life behaves very differently from one with a 6-day half-life — both in how to time injections for maximum effect and in how frequently re-dosing is needed. This reference covers half-lives for all commonly researched peptides and explains the practical dosing implications of each.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
For subcutaneous peptides, food co-ingestion is generally irrelevant — SubQ absorption is not meaningfully affected by meal timing. For oral peptides (MK-677, oral BPC-157), food may slow absorption and reduce peak concentration, though for compounds taken chronically, this often doesn't matter significantly. Specific compounds (GHRP-6) work best fasted to avoid insulin-mediated blunting of GH response. Practically: a peptide with a 30-minute half-life injected subcutaneously produces effects for approximately 2–3 hours. Half-life is the time required for blood plasma concentration of a compound to fall to 50% of its peak value. Products ship from the USA with published purity certificates. Practically: a peptide with a 30-minute half-life injected subcutaneously produces effects for approximately 2–3 hours. Their value derives from stimulating pulsatile GH release — ideally coinciding with the natural nocturnal GH surge that occurs in the first 1–2 hours of deep sleep.
Why Half-Life Matters for Peptides
Half-life is the time required for blood plasma concentration of a compound to fall to 50% of its peak value. After approximately 4–5 half-lives, a compound has cleared to near-negligible concentrations (<5% of peak). For research peptides injected subcutaneously, the "effective duration" of action is typically 4–6 half-lives from peak absorption, which itself occurs 30–90 minutes post-injection depending on the peptide.
Practically: a peptide with a 30-minute half-life injected subcutaneously produces effects for approximately 2–3 hours. A peptide with a 2-hour half-life produces effects for 8–10 hours. One with a 6-day half-life (CJC-1295 with DAC) requires weekly rather than daily injection. Understanding this determines whether single-dose daily is appropriate, split dosing is needed, and what time of day administration is optimal for the intended mechanism.
Half-Life and Timing for GH Secretagogues
GH secretagogues are particularly timing-sensitive. Their value derives from stimulating pulsatile GH release — ideally coinciding with the natural nocturnal GH surge that occurs in the first 1–2 hours of deep sleep. For short-half-life GHRHs and GHRPs (Sermorelin 10–20 min, GHRP-2/GHRP-6 ~30 min, Ipamorelin ~2 hours), pre-sleep injection 30 minutes before lights-out is standard practice to time the pulsatile GH release during peak natural GH secretion. CJC-1295 without DAC (30–45 minutes half-life) also requires pre-sleep timing. CJC-1295 with DAC (6–8 days) is injected once weekly and does not require timing to sleep.
Implications for Split Dosing
Some compounds benefit from split dosing to maintain more consistent blood levels. BPC-157 at twice-daily dosing (morning and pre-sleep) maintains more continuous tissue exposure than single daily dosing — relevant for chronic injury treatment where sustained tissue-level peptide availability is beneficial. Selank and Semax with 2–4 hour effective durations are naturally suited to morning dosing for work performance, with optional afternoon re-dose for extended cognitive demands. MK-677 (ghrelin mimetic, oral, 24-hour half-life) is typically once-daily, most often pre-sleep to leverage nocturnal GH pulse enhancement.
Peptide Half-Life Reference
| Peptide | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| BPC-157 | ~30–60 min | SubQ/IM | Once or twice daily | Morning + pre-sleep split is common |
| TB-500 | ~2–3 days | SubQ | 2–3× per week | Long half-life; no daily dosing needed |
| Sermorelin | 10–20 min | SubQ | Once daily — pre-sleep | Strictly pre-sleep for GH pulse |
| CJC-1295 (no DAC) | 30–45 min | SubQ | Once daily — pre-sleep | Short active window; pre-sleep critical |
| CJC-1295 (with DAC) | 6–8 days | SubQ | Once weekly | No timing requirement |
| Ipamorelin | ~2 hours | SubQ | Once or twice daily | Pre-sleep preferred; morning optional |
| GHRP-2 / GHRP-6 | ~30 min | SubQ | 2–3× daily | Fasting important for GHRP-6 hunger effect |
| MK-677 | ~24 hours (oral) | Oral | Once daily — pre-sleep | Pre-sleep for GH pulse; oral convenience |
| Semax | ~2–4 hours (IN) | Intranasal | Once or twice daily | Morning dose standard; afternoon optional |
| Selank | ~1–3 hours (IN) | Intranasal | Once or twice daily | As-needed; pre-task dosing effective |
| Epithalon | ~1 hour | SubQ/IV | Once daily (during course) | Morning or evening dosing both used |
| GHK-Cu | ~30–60 min | SubQ or topical | Once daily (SubQ) | Topical provides different kinetics |
| IGF-1 LR3 | 20–30 hours | SubQ | Once daily or every other day | Long half-life; spacing important |
| PT-141 | ~2.7 hours | SubQ | As-needed, pre-activity | Administer 45–90 min before activity |
| Semaglutide | ~7 days | SubQ | Once weekly | Consistent day each week recommended |
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Safety Implications of Peptide Half-Life
Why Half-Life Matters for Safety: A peptide's half-life directly determines its duration of action, peak concentration, and accumulation potential — all of which have significant safety implications. Misunderstanding half-life can lead to both under-dosing (reducing efficacy) and over-dosing (increasing side effect risk), and can create dangerous accumulation patterns with repeated administration.
Key Safety Considerations:
- Accumulation with long half-life peptides: Peptides with extended half-lives (such as CJC-1295 with DAC, semaglutide, or tirzepatide) accumulate with repeated dosing, reaching steady-state concentrations 4-5 times higher than single-dose levels. Side effects may intensify as the compound accumulates, appearing days or weeks into a protocol rather than immediately. This accumulation also means that adverse effects persist longer after discontinuation.
- Dosing frequency errors: Applying short half-life dosing frequencies to long half-life compounds (or vice versa) is a common and potentially dangerous mistake. For example, dosing CJC-1295 with DAC (half-life ~8 days) on a daily schedule designed for CJC-1295 without DAC (half-life ~30 minutes) would result in massive compound accumulation.
- Modified peptides and unexpected kinetics: PEGylated, acetylated, or otherwise modified peptides often have dramatically different half-lives than their parent compounds. Assuming identical pharmacokinetics between a modified and unmodified peptide can lead to significant dosing errors.
- Individual variation: Half-life values reported in research represent population averages. Individual factors including body composition, renal function, hepatic function, and injection site can significantly alter actual half-life, making personalized monitoring important.
Renal and Hepatic Considerations: Most peptides are cleared through renal filtration or hepatic metabolism. Individuals with impaired kidney or liver function may experience significantly extended half-lives and increased accumulation risk. Dose reductions or extended dosing intervals may be necessary, and regular monitoring of organ function is advisable.
Half-life data for research peptides is often derived from limited studies, animal models, or theoretical calculations rather than comprehensive human pharmacokinetic studies. Actual half-lives in individual users may differ significantly from published values. This guide is for educational purposes only. Consult a healthcare provider for personalized dosing guidance based on your specific health profile.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions
Not necessarily — it depends on the desired pharmacological profile. For GH secretagogues, short half-life preserves physiological pulsatility which is actually considered an advantage over long-acting versions for chronic use. For TGF-β-driven tissue repair peptides like BPC-157, longer effective duration may be advantageous. Half-life is a pharmacokinetic property, not a quality metric.
For subcutaneous peptides, food co-ingestion is generally irrelevant — SubQ absorption is not meaningfully affected by meal timing. For oral peptides (MK-677, oral BPC-157), food may slow absorption and reduce peak concentration, though for compounds taken chronically, this often doesn't matter significantly. Specific compounds (GHRP-6) work best fasted to avoid insulin-mediated blunting of GH response.
CJC-1295 with DAC uses a Drug Affinity Complex — a reactive maleimide group that covalently binds to albumin (the most abundant blood protein) after injection. Once bound to albumin, the peptide shares albumin's 19-day half-life rather than being rapidly degraded. This allows once-weekly injection but creates continuous GHRH receptor activation without pulsatility, which some researchers consider a disadvantage.